Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

NCT01449071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: Epratuzumab 400 mg
BIOLOGICAL: Epratuzumab 1200 mg
BIOLOGICAL: Epratuzumab 100 mg
BIOLOGICAL: Epratuzumab 600 mg

Sponsor

UCB Pharma